Drugs / Drug 601
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04151407 | Mar 2019 → Dec 2020 | diabetic macular edema | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04468997 | Nov 2018 → Mar 2021 | wet macular degeneration | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Drug 601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04468997 ↗ |
| Action | Inhibit | “Recombinant humanized anti-VEGF monoclonal antibody” NCT04151407 ↗ |
| Modality | Monoclonal antibody | “Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.” NCT04151407 ↗ |
| Route | Other | “Vitreous injection” NCT04151407 ↗ |